Hossein Borghaei, DO, MS, Offers His Advice on Staying Up to Date With Lung Cancer Research
CancerNetwork® sat down with Hossein Borghaei, DO, MS, to talk about keeping track of conference and journal updates to help build and maintain knowledge around lung cancer.
CancerNetwork® spoke with Hossein Borghaei, DO, MS, of the Fox Chase Cancer Center and Thoracic Malignancies Chair for the journal ONCOLOGY®, about how clinicians can keep up with current trends in lung cancer by participating in various conferences, reading pertinent journal articles, and keeping up to date with social media.
Transcript:
Don’t miss updates. Lung cancer treatment is moving very quickly. There are a lot of nuances now and it’s not as simple as giving the same chemotherapy to everybody. These updates can be very important from various meetings, such as [the American Society of Clinical Oncology Annual Meeting, the World Conference on Lung Cancer, the European Society for Medical Oncology Congress, and American Association for Cancer Research Annual Meeting] because it could have an impact on clinical practice and patient care. Staying up to date is even more important in the world of lung cancer. In the last 10 to 12 years, we’ve seen a lot of changes in lung cancer and I’m hoping that the evolution will continue. We’re going to see refinement with more drugs and more methods made available for assessments. I think it’s important to stay up to date, which is why programs like CME and some of the other things that are done is quite important, especially reading the actual journal articles and summaries that are provided. I think those are all good.
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
